Sabrina Kuttruff-Coqui, Ph.D.

Senior Director Capital Markets & Business Planning

Sabrina Kuttruff-Coqui joined Immatics in 2009 and coordinates the Business Planning and Capital Markets activities for Immatics. In this role, she served as transaction lead for the merger between Immatics & Arya and supported the company in getting public.

Sabrina is a scientist at heart and has been active in the field of cancer immunotherapy for more than 10 years. She designed a project for ultra-personalized vaccination of Glioblastoma patients (GAPVAC) and successfully applied for a €6m grant by the European commission. Sabrina was a key contributor in setting up the business plan for Immatics US Inc resulting in a $20m CPRIT grant by the State of Texas. As Director Program Management she moved to Houston and led the team translating the Immatics´ front runner ACT trial from preclinical into clinical development. After sailing around the world with her family, Sabrina re-joined Immatics Germany in Autumn 2019. Since then she and her team focused in translating Immatics from a private into a public company.

Sabrina holds a Diploma in Biochemistry and received her Ph.D in Immunology from the University of Tuebingen, Germany.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.